Search Site

Search form

Current Press Releases

All Releases
View Summary David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Dec 15, 2014
PDF 10.6 KB
View Summary Vertex to Present at Deutsche Bank BioFEST on December 2
Nov 20, 2014
PDF 6.9 KB
View Summary Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Nov 5, 2014
PDF 14.5 KB
View Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Oct 30, 2014
PDF 6.9 KB
View Summary Vertex Reports Third Quarter 2014 Financial Results
Oct 28, 2014
PDF 61.9 KB
View Summary FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Oct 21, 2014
PDF 19.3 KB
View Summary Vertex to Announce Third Quarter 2014 Financial Results on October 28
Oct 14, 2014
PDF 6.8 KB
View Summary Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis
Oct 9, 2014
PDF 70.1 KB
View Summary Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Sep 8, 2014
PDF 67.0 KB
View Summary Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Sep 2, 2014
PDF 6.8 KB
View Summary Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jul 31, 2014
PDF 20.4 KB
View Summary Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs
Jul 29, 2014
PDF 64.9 KB
View Summary Vertex to Announce Second Quarter 2014 Financial Results on July 29
Jul 14, 2014
PDF 6.9 KB
View Summary Vertex Announces Retirement of Peter Mueller, Ph.D.
Jul 10, 2014
PDF 8.7 KB
View Summary Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation
Jun 30, 2014
PDF 19.5 KB
View Summary Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations
Jun 27, 2014
PDF 20.3 KB
View Summary Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
Jun 24, 2014
PDF 76.2 KB
View Summary Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza
Jun 18, 2014
PDF 15.6 KB
View Summary Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis
Jun 16, 2014
PDF 20.1 KB
View Summary Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference
Jun 12, 2014
PDF 24.3 KB
Showing 1-20 of 35 Page: 1 2  Next 20